Phio Pharmaceuticals Corp. 8-K Summary
Business Context and Reporting Period
Phio Pharmaceuticals Corp. (PHIO) filed a Current Report on Form 8-K on November 10, 2021. The filing announces the release of financial results for the period ended September 30, 2021. The company is incorporated in Delaware and trades on the NASDAQ Capital Market.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) for detailed data. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this text. The filing text does not provide a clear value for these metrics.
Material Changes
No material changes versus the prior comparable period are detailed in this specific document. The filing indicates that the results are contained within the attached press release, which is not included in the input text.
Guidance, Outlook, and Risks
This 8-K filing does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies. It strictly notifies investors of the availability of the Q3 2021 results via the referenced press release.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 10, 2021) for actual revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full report.
- Confirm if the company has issued any updated financial guidance alongside the results.